{"id":"https://openalex.org/W4310103284","doi":"https://doi.org/10.1182/blood-2022-158626","title":"A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure","display_name":"A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310103284","doi":"https://doi.org/10.1182/blood-2022-158626"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-158626","doi":"https://doi.org/10.1182/blood-2022-158626","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-158626","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084588977","display_name":"Jan Philipp Bewersdorf","orcid":"https://orcid.org/0000-0003-3352-0902","observed_orcids":["https://orcid.org/0000-0003-3352-0902"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan Philipp Bewersdorf","raw_affiliation_strings":["1Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY","2Department of Internal Medicine, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven, CT","Department of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"2Department of Internal Medicine, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]},{"raw_affiliation_string":"Department of Medicine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091021372","display_name":"Rory Michael Shallis","orcid":"https://orcid.org/0000-0002-8542-2944","observed_orcids":["https://orcid.org/0000-0002-8542-2944"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rory Michael Shallis","raw_affiliation_strings":["3Department of Internal Medicine, School of Medicine and Yale Cancer Center, Yale University, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Internal Medicine, School of Medicine and Yale Cancer Center, Yale University, New Haven, CT","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022594161","display_name":"Elad Sharon","orcid":"https://orcid.org/0000-0002-0044-9719","observed_orcids":["https://orcid.org/0000-0002-0044-9719"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elad Sharon","raw_affiliation_strings":["4Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083539058","display_name":"Anne Barman Caldwell","orcid":"https://orcid.org/0000-0003-3120-3946","observed_orcids":["https://orcid.org/0000-0003-3120-3946"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Caldwell","raw_affiliation_strings":["5Yale Cancer Center, Yale University, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Yale Cancer Center, Yale University, New Haven, CT","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073006325","display_name":"Wei Wei","orcid":"https://orcid.org/0000-0003-1263-5620","observed_orcids":["https://orcid.org/0000-0003-1263-5620"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Wei","raw_affiliation_strings":["6Department of Biostatistics, Yale School of Public Health, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Department of Biostatistics, Yale School of Public Health, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071257161","display_name":"Abdulraheem Yacoub","orcid":"https://orcid.org/0000-0001-5293-4620","observed_orcids":["https://orcid.org/0000-0001-5293-4620"]},"institutions":[{"id":"https://openalex.org/I4210097601","display_name":"The University of Kansas Cancer Center","ror":"https://ror.org/00cj35179","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210097601"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdulraheem Yacoub","raw_affiliation_strings":["7The University of Kansas Cancer Center, Leawood, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7The University of Kansas Cancer Center, Leawood, KS","institution_ids":["https://openalex.org/I4210097601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090985347","display_name":"Yazan F. Madanat","orcid":"https://orcid.org/0000-0001-9573-2690","observed_orcids":["https://orcid.org/0000-0001-9573-2690"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yazan F. Madanat","raw_affiliation_strings":["8Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040303721","display_name":"Joshua F. Zeidner","orcid":"https://orcid.org/0000-0002-9014-1514","observed_orcids":["https://orcid.org/0000-0002-9014-1514"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua F. Zeidner","raw_affiliation_strings":["9UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025780450","display_name":"Jessica Kaplan Altman","orcid":"https://orcid.org/0000-0003-1987-1896","observed_orcids":["https://orcid.org/0000-0003-1987-1896"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica K. Altman","raw_affiliation_strings":["10Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060015628","display_name":"Olatoyosi M. Odenike","orcid":"https://orcid.org/0000-0002-4027-4124","observed_orcids":["https://orcid.org/0000-0002-4027-4124"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olatoyosi Odenike","raw_affiliation_strings":["11Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068248858","display_name":"Swaroopa Yerrabothala","orcid":"https://orcid.org/0000-0003-4622-2787","observed_orcids":["https://orcid.org/0000-0003-4622-2787"]},"institutions":[{"id":"https://openalex.org/I1289422878","display_name":"Dartmouth\u2013Hitchcock Medical Center","ror":"https://ror.org/00d1dhh09","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I107672454","https://openalex.org/I1289422878","https://openalex.org/I4390039337"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Swaroopa Yerrabothala","raw_affiliation_strings":["12Hematology Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Hematology Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH","institution_ids":["https://openalex.org/I1289422878"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110302760","display_name":"Tibor J. Kovacsovics","orcid":"https://orcid.org/0000-0003-3294-0761","observed_orcids":["https://orcid.org/0000-0003-3294-0761"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tibor Kovacsovics","raw_affiliation_strings":["13Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University Of Utah, Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University Of Utah, Salt Lake City, UT","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015755664","display_name":"Nikolai Alexandrovich Podoltsev","orcid":"https://orcid.org/0000-0002-3657-778X","observed_orcids":["https://orcid.org/0000-0002-3657-778X"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikolai A. Podoltsev","raw_affiliation_strings":["14Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, Madison, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, Madison, CT","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054557581","display_name":"Stephanie Halene","orcid":"https://orcid.org/0000-0002-2737-9810","observed_orcids":["https://orcid.org/0000-0002-2737-9810"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie Halene","raw_affiliation_strings":["15Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"15Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050726526","display_name":"Richard F. Little","orcid":"https://orcid.org/0000-0002-4091-1699","observed_orcids":["https://orcid.org/0000-0002-4091-1699"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard F. Little","raw_affiliation_strings":["16Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"16Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046042179","display_name":"Richard Piekarz","orcid":"https://orcid.org/0000-0002-3591-7893","observed_orcids":["https://orcid.org/0000-0002-3591-7893"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Piekarz","raw_affiliation_strings":["17Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"17Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101760493","display_name":"Steven D. Gore","orcid":"https://orcid.org/0000-0002-3649-8758","observed_orcids":["https://orcid.org/0000-0002-3649-8758"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven D. Gore","raw_affiliation_strings":["16Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"16Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057178417","display_name":"Tae Kon Kim","orcid":"https://orcid.org/0000-0002-5182-3870","observed_orcids":["https://orcid.org/0000-0002-5182-3870"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tae Kon Kim","raw_affiliation_strings":["18Division of hematology/oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"18Division of hematology/oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067521829","display_name":"Amer Methqal Zeidan","orcid":"https://orcid.org/0000-0001-7017-8160","observed_orcids":["https://orcid.org/0000-0001-7017-8160"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amer M. Zeidan","raw_affiliation_strings":["19Yale University and Yale Cancer Center, East Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"19Yale University and Yale Cancer Center, East Haven, CT","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":16,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.1858,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.51087498,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"9084","last_page":"9086"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.006599999964237213,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/entinostat","display_name":"entinostat","score":0.9480000138282776},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9490000009536743},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.8899999856948853},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.9160000085830688},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9589999914169312},{"id":"https://openalex.org/keywords/refractory-disease","display_name":"refractory disease","score":0.5070000290870667},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.996999979019165},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.5849999785423279},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6330000162124634},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8939999938011169},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6549999713897705}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8008333444595337},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6949023008346558},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.549979567527771},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5408182144165039},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.44005540013313293},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43474462628364563},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4305097162723541},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.42611241340637207},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.42353206872940063},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3711482286453247},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.30163800716400146},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.29652494192123413},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.24161362648010254},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-158626","doi":"https://doi.org/10.1182/blood-2022-158626","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-158626","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4386052367","https://openalex.org/W4389241247","https://openalex.org/W4405039256","https://openalex.org/W3095797672","https://openalex.org/W2907680868","https://openalex.org/W3028273055","https://openalex.org/W2987518512","https://openalex.org/W2742157481","https://openalex.org/W3211894877","https://openalex.org/W3191602849"],"abstract_inverted_index":{"Introduction:":[0],"Pts":[1,134],"with":[2,16,67,89,119,181,193,361,587],"MDS":[3,41,90,120,278,324,343,377,671],"and":[4,11,25,48,83,94,110,129,142,161,175,215,279,289,313,325,329,336,344,385,414,441,456,549,615,619,672,702],"HMA":[5,95,130,360,677],"failure":[6,131,510,547],"have":[7,137],"a":[8,270,306,470,599,611,635],"poor":[9],"prognosis":[10],"need":[12],"novel":[13],"therapies.":[14],"Success":[15],"anti-PD1":[17,53,84],"therapy":[18,54,476],"in":[19,87,253,323,327,331,390,400,490,517,526,559,565,572,670],"myeloid":[20],"malignancies":[21],"has":[22,69],"been":[23,70],"limited":[24,689],"resistance":[26,51],"mechanisms":[27],"are":[28,388,659],"poorly":[29],"understood.":[30],"Preclinical":[31],"data":[32,704],"suggest":[33],"that":[34],"myeloid-derived":[35],"suppressor":[36],"cells":[37],"(MDSCs)":[38],"contribute":[39],"to":[40,52,73,136,203,218,234,277,407,501,581,617],"progression":[42,410,489],"(Chen":[43],"et":[44,56],"al.":[45,57],"JCI":[46],"2013).":[47],"may":[49],"mediate":[50],"(Kim":[55],"PNAS":[58],"2014).":[59],"As":[60],"HDACi":[61,81],"decrease":[62],"MDSCs,":[63],"synergistic":[64],"anti-tumor":[65],"efficacy":[66,591],"anti-PD-1":[68],"hypothesized":[71],"leading":[72],"this":[74,664],"phase":[75,112,666],"Ib":[76,113],"study":[77],"(NCT02936752)":[78],"of":[79,163,177,188,227,263,291,308,370,472,475,484,521,540,554,576,613,638,708],"the":[80,228,259,292,300,318,465,497,514,522,584,588,697,700],"entinostat":[82,155,168,202,679,709],"antibody":[85],"pembrolizumab":[86,182,254,681],"pts":[88,118,199,341,356,363,378,397,416,433,459,468,494,561,586,604,625,675],"or":[91,121,249,256],"oligoblastic":[92,122,673],"AML":[93,123,674],"failure.":[96],"Methods:":[97],"We":[98],"conducted":[99],"an":[100],"investigator-initiated,":[101],"NCI-Cancer":[102],"Therapy":[103],"Evaluation":[104],"Program":[105],"(NCI-CTEP)-sponsored,":[106],"multicenter,":[107],"dose":[108,152,394,450],"escalation":[109],"expansion":[111],"trial.":[114],"Adult":[115],"(\u226518":[116],"years)":[117],"(bone":[124],"marrow":[125],"[BM]":[126],"blasts":[127,608],"20-30%)":[128],"were":[132,213,223,268,275,398,417,445,460,531,543,557,570,578],"enrolled.":[133],"had":[135,357,366,605,626,631,688],"adequate":[138],"end":[139],"organ":[140],"function":[141],"ECOG":[143],"performance":[144],"status":[145],"\u22642.":[146],"The":[147,284,296,480,533],"dose-escalation":[148],"part":[149],"used":[150],"2":[151,261,432,499,566,603],"levels":[153],"(DL1:":[154],"8mg":[156,169],"PO":[157,170],"on":[158,171,185,207,419,425],"days":[159,172],"1":[160,187,423,507],"8":[162,575],"each":[164,178,189],"21-day":[165,179,190],"cycle;":[166],"DL2:":[167],"1,":[173,198],"8,":[174],"15":[176,458],"cycle)":[180],"200mg":[183],"IV":[184],"day":[186],"cycle":[191,194,197],"starting":[192],"2.":[195,528],"In":[196,663],"received":[200,358,469],"only":[201,272],"determine":[204],"its":[205],"impact":[206],"MDSCs":[208,328],"separately":[209],"from":[210,505,508,610],"pembrolizumab.":[211,711],"Toxicities":[212],"tabulated":[214],"graded":[216],"according":[217],"CTCAE-5.":[219],"Dose-limiting":[220],"toxicities":[221],"(DLT)":[222],"defined":[224,304],"as":[225,305],"any":[226,242,250,555],"following":[229],"if":[230,273],"deemed":[231],"possibly":[232],"related":[233,245],"trial":[235,669],"therapy:":[236],"Grade":[237],"(G)":[238],"3/4":[239],"non-hematologic":[240,536],"toxicity,":[241],"\u2265G3":[243,537],"immune":[244],"adverse":[246],"events":[247],"(IrAEs)":[248],"IrAE":[251],"resulting":[252],"interruption":[255],"discontinuation":[257,486],"during":[258,411,449,496],"first":[260,589],"cycles":[262,474],"combined":[264],"therapy.":[265,371],"Hematologic":[266,529],"AEs":[267,523,530,538,569],"considered":[269],"DLT":[271,412,424,515],"they":[274],"unrelated":[276],"lasted":[280],"for":[281,376],">42":[282],"days.":[283],"primary":[285],"endpoint":[286,298],"was":[287,299,349,379,422,454,487,648,684],"safety":[288],"determination":[290],"maximum":[293],"tolerated":[294,686],"dose.":[295],"secondary":[297],"overall":[301],"response":[302,321],"rate":[303],"composite":[307],"complete":[309],"remission,":[310,312],"partial":[311],"hematologic":[314,447],"improvement":[315],"(HI)":[316],"per":[317],"2006":[319],"IWG":[320],"criteria":[322],"change":[326],"PD1/PDL-1":[330],"BM.":[332],"Results:":[333],"Between":[334],"06/26/2017":[335],"02/03/2021,":[337],"we":[338],"enrolled":[339,399,461],"28":[340],"(25":[342],"3":[345,473,594],"AML).":[346],"Median":[347,372],"age":[348],"74":[350],"years":[351],"(range":[352],"[R],":[353],"57-86),":[354],"all":[355],"prior":[359,368],"5":[362,560,630],"(18%)":[364],"having":[365],"\u22653":[367],"lines":[369],"IPSS-R":[373],"at":[374,436,462,682],"screening":[375],"5.5":[380],"(R:":[381,477,641],"2-10).":[382],"Baseline":[383],"demographic":[384],"clinical":[386,703],"characteristics":[387],"shown":[389],"Table":[391,527],"1.":[392],"During":[393],"escalation,":[395],"7":[396],"DL1":[401,426,453,683],"(1":[402,504],"pt":[403,597],"not":[404],"evaluable":[405],"due":[406,500],"early":[408],"disease":[409,488],"period),":[413],"6":[415],"treated":[418],"DL2.":[420],"There":[421,444],"(G5":[427],"pneumonia/bronchoalveolar":[428],"hemorrhage":[429],"(BAH),":[430],"while":[431,629],"experienced":[434],"DLTs":[435,448],"DL2":[437],"(G3":[438],"pharyngeal":[439],"mucositis":[440],"G3":[442,563],"anorexia).":[443],"no":[446,596],"escalation.":[451],"Thus,":[452],"expanded,":[455],"another":[457],"DL1.":[463],"Across":[464],"entire":[466],"study,":[467,498],"median":[471,636,646],"1-12":[478],"cycles).":[479],"most":[481,534],"frequent":[482],"cause":[483],"treatment":[485,541],"9":[491],"pts.":[492,567],"Four":[493],"died":[495],"therapy-related":[502],"complications":[503],"pneumonia/BAH,":[506],"multi-organ":[509],"which":[511,577],"occurred":[512],"after":[513,593,676],"period":[516],"DL2).":[518],"A":[519],"summary":[520],"is":[524],"presented":[525],"common.":[532],"common":[535],"independent":[539],"attribution":[542],"infection":[544],"(32.1%),":[545],"hypoxia/respiratory":[546],"(10.7%)":[548],"dyspnea":[550],"(10.7%).":[551],"Potential":[552],"IrAEs":[553],"grade":[556],"reported":[558,571],"including":[562],"pneumonitis":[564],"Serious":[568],"14":[573],"pts;":[574],"potentially":[579],"attributed":[580],"treatment.":[582],"Among":[583],"19":[585],"BM":[590],"assessment":[592],"months,":[595],"achieved":[598],"protocol-defined":[600],"response.":[601],"However,":[602],"mCR":[606],"(BM":[607],"decreased":[609],"baseline":[612],"7%":[614],"10%":[616],"2%":[618],"4%,":[620],"respectively)":[621],"without":[622],"HI.":[623],"Twelve":[624],"stable":[627],"disease,":[628],"progressive":[632],"disease.":[633],"With":[634],"follow-up":[637],"5.9":[639],"months":[640,650],"0.5":[642],"-":[643,654],"59.1":[644],"months),":[645],"OS":[647],"6.9":[649],"(95%":[651],"CI:":[652],"4.8":[653],"13.6":[655],"months).":[656],"Correlative":[657],"studies":[658],"being":[660],"conducted.":[661],"Conclusion:":[662],"multi-center":[665],"1b":[667],"investigator-initiated":[668],"failure,":[678],"+":[680,710],"reasonably":[685],"but":[687],"therapeutic":[690],"efficacy.":[691],"Ongoing":[692],"correlative":[693],"work":[694],"will":[695],"explore":[696],"disconnect":[698],"between":[699],"preclinical":[701],"regarding":[705],"potential":[706],"synergy":[707],"Figure":[712],"1View":[713,716],"largeDownload":[714,717],"PPTFigure":[715],"PPT":[718],"Close":[719],"modal":[720]},"counts_by_year":[{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-11-30T00:00:00"}